Skip to content

Study · Not a test of the peptide alone · 2026

8 results

The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review.

Weber L, Hashemnia Sharbabaki M, Fuchs B, Alberton P, Giunta R, Mert S, Thierfelder N

Stem cell reviews and reports23 Oct 2025Cited by 3 (Europe PMC)

PMID41129073 (opens in a new tab)PMCIDPMC12795975 (opens in a new tab)DOI10.1007/s12015-025-11002-7 (opens in a new tab)PepBankPUB-41129073
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

BackgroundGlucagon-like peptide-1 receptor agonists, originally developed for managing type 2 diabetes, have gained attention for their weight-reducing and broader biological effects. Among these, their influence on human mesenchymal stem cells remains underexplored, despite the critical role of mesenchymal stem cells in tissue regeneration and secretion of bioactive factors.MethodsThis systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify and evaluate in vitro studies investigating the effects of glucagon-like peptide-1 receptor agonists and their analogues on human mesenchymal stem cell functions, including proliferation, differentiation, signaling, apoptosis, and tissue-specific applications. Risk of bias was assessed using an adapted Quality Assessment Tool for In Vitro Studies (QUIN) tool.ResultsThirty-eight eligible studies were identified. Glucagon-like-peptide-1 receptor agonist, like native glucagon-like peptide-1, Exendin-4, and Liraglutide, exert context-, dose-, and timing-dependent effects on human mesenchymal stem cells. They modulate proliferation and overall promote osteogenesis while inhibiting adipogenesis. Key pathways, including Wnt/β-catenin, bone morphogenetic protein 2/Smad, phosphoinositide 3-kinase/Akt and protein kinase A, play a role in this. Furthermore, these agents modulate inflammation, reduce apoptosis, and improve stem cell functions even under diabetic or inflammatory conditions. Exendin-4 facilitated tenogenic and insulin-producing cell differentiation, particularly in engineered scaffolds or genetically engineered human mesenchymal stem cells.ConclusionGlucagon-like peptide-1 receptor agonists modulate key pathways in human mesenchymal stem cells to influence survival, differentiation, and metabolic function, suggesting promising therapeutic potential beyond glycemic control. However, heterogeneous experimental designs and limited translational data necessitate further standardized and in vivo research to define clinical applications.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01LabNot a test of Liraglutide aloneIn vitro (cells)Other

    Across human mesenchymal stem cell studies, GLP-1 receptor agonists including liraglutide had context-, dose-, and timing-dependent effects.

    In plain wordsIn lab tests, GLP-1 drugs including liraglutide had effects that varied by context, dose, and timing.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedMesenchymal stem cell effects
    Study

    humann: not reported in source

    human mesenchymal stem cells
    Outcome group
    Overall treatment effect · Whole body

    Source sentences

    Summary
    Glucagon-like-peptide-1 receptor agonist, like native glucagon-like peptide-1, Exendin-4, and Liraglutide, exert context-, dose-, and timing-dependent effects on human mesenchymal stem cells.
    2 context sentences
    Summary · context
    This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify and evaluate in vitro studies investigating the effects of glucagon-like peptide-1 receptor agonists and their analogues on human mesenchymal stem cell functions, including proliferation, differentiation, signaling, apoptosis, and tissue-specific applications.
    Summary · context
    Thirty-eight eligible studies were identified.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02LabNot a test of Liraglutide aloneIn vitro (cells)Efficacy outcome

    Across human mesenchymal stem cell studies, GLP-1 receptor agonists including liraglutide modulated proliferation.

    In plain wordsIn lab tests, GLP-1 drugs including liraglutide changed stem-cell proliferation.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedMesenchymal stem cell proliferation
    Study

    humann: not reported in source

    human mesenchymal stem cells
    Outcome group
    Cell proliferation and differentiation · Whole body

    Source sentences

    Summary
    They modulate proliferation and overall promote osteogenesis while inhibiting adipogenesis.
    2 context sentences
    Summary · context
    Glucagon-like-peptide-1 receptor agonist, like native glucagon-like peptide-1, Exendin-4, and Liraglutide, exert context-, dose-, and timing-dependent effects on human mesenchymal stem cells.
    Summary · context
    This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify and evaluate in vitro studies investigating the effects of glucagon-like peptide-1 receptor agonists and their analogues on human mesenchymal stem cell functions, including proliferation, differentiation, signaling, apoptosis, and tissue-specific applications.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03LabNot a test of Liraglutide aloneIn vitro (cells)Efficacy outcome

    Across human mesenchymal stem cell studies, GLP-1 receptor agonists including liraglutide promoted osteogenesis.

    In plain wordsIn lab tests, GLP-1 drugs including liraglutide promoted bone-cell formation.

    Peptide
    Liraglutide
    Outcome
    IncreaseOsteogenesis
    Study

    humann: not reported in source

    human mesenchymal stem cells
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    They modulate proliferation and overall promote osteogenesis while inhibiting adipogenesis.
    2 context sentences
    Summary · context
    Glucagon-like-peptide-1 receptor agonist, like native glucagon-like peptide-1, Exendin-4, and Liraglutide, exert context-, dose-, and timing-dependent effects on human mesenchymal stem cells.
    Summary · context
    This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify and evaluate in vitro studies investigating the effects of glucagon-like peptide-1 receptor agonists and their analogues on human mesenchymal stem cell functions, including proliferation, differentiation, signaling, apoptosis, and tissue-specific applications.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04LabNot a test of Liraglutide aloneIn vitro (cells)Efficacy outcome

    Across human mesenchymal stem cell studies, GLP-1 receptor agonists including liraglutide inhibited adipogenesis.

    In plain wordsIn lab tests, GLP-1 drugs including liraglutide reduced fat-cell formation.

    Peptide
    Liraglutide
    Outcome
    DecreaseAdipogenesis
    Study

    humann: not reported in source

    human mesenchymal stem cells
    Outcome group
    Cell proliferation and differentiation · Metabolic and weight

    Source sentences

    Summary
    They modulate proliferation and overall promote osteogenesis while inhibiting adipogenesis.
    2 context sentences
    Summary · context
    Glucagon-like-peptide-1 receptor agonist, like native glucagon-like peptide-1, Exendin-4, and Liraglutide, exert context-, dose-, and timing-dependent effects on human mesenchymal stem cells.
    Summary · context
    This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify and evaluate in vitro studies investigating the effects of glucagon-like peptide-1 receptor agonists and their analogues on human mesenchymal stem cell functions, including proliferation, differentiation, signaling, apoptosis, and tissue-specific applications.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05LabNot a test of Liraglutide aloneIn vitro (cells)Mechanism

    Across human mesenchymal stem cell studies, Wnt, BMP2/Smad, PI3K/Akt, and PKA pathways played a role in effects of GLP-1 receptor agonists including liraglutide.

    In plain wordsIn lab tests, several signalling pathways contributed to effects of GLP-1 drugs including liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableWnt, BMP2/Smad, PI3K/Akt, and PKA pathways
    Study

    humann: not reported in source

    human mesenchymal stem cells
    Outcome group
    Receptor activity and mechanism · Whole body

    Source sentences

    Summary
    Key pathways, including Wnt/β-catenin, bone morphogenetic protein 2/Smad, phosphoinositide 3-kinase/Akt and protein kinase A, play a role in this.
    2 context sentences
    Summary · context
    Glucagon-like-peptide-1 receptor agonist, like native glucagon-like peptide-1, Exendin-4, and Liraglutide, exert context-, dose-, and timing-dependent effects on human mesenchymal stem cells. They modulate proliferation and overall promote osteogenesis while inhibiting adipogenesis.
    Summary · context
    This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify and evaluate in vitro studies investigating the effects of glucagon-like peptide-1 receptor agonists and their analogues on human mesenchymal stem cell functions, including proliferation, differentiation, signaling, apoptosis, and tissue-specific applications.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06LabNot a test of Liraglutide aloneIn vitro (cells)Efficacy outcome

    Across human mesenchymal stem cell studies, GLP-1 receptor agonists including liraglutide modulated inflammation.

    In plain wordsIn lab tests, GLP-1 drugs including liraglutide changed inflammation.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedInflammation
    Study

    humann: not reported in source

    human mesenchymal stem cells
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Furthermore, these agents modulate inflammation, reduce apoptosis, and improve stem cell functions even under diabetic or inflammatory conditions.
    2 context sentences
    Summary · context
    Glucagon-like-peptide-1 receptor agonist, like native glucagon-like peptide-1, Exendin-4, and Liraglutide, exert context-, dose-, and timing-dependent effects on human mesenchymal stem cells.
    Summary · context
    This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify and evaluate in vitro studies investigating the effects of glucagon-like peptide-1 receptor agonists and their analogues on human mesenchymal stem cell functions, including proliferation, differentiation, signaling, apoptosis, and tissue-specific applications.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07LabNot a test of Liraglutide aloneIn vitro (cells)Efficacy outcome

    Across human mesenchymal stem cell studies, GLP-1 receptor agonists including liraglutide reduced apoptosis.

    In plain wordsIn lab tests, GLP-1 drugs including liraglutide reduced cell death.

    Peptide
    Liraglutide
    Outcome
    DecreaseApoptosis
    Study

    humann: not reported in source

    human mesenchymal stem cells
    Outcome group
    Cell proliferation and differentiation · Whole body

    Source sentences

    Summary
    Furthermore, these agents modulate inflammation, reduce apoptosis, and improve stem cell functions even under diabetic or inflammatory conditions.
    2 context sentences
    Summary · context
    Glucagon-like-peptide-1 receptor agonist, like native glucagon-like peptide-1, Exendin-4, and Liraglutide, exert context-, dose-, and timing-dependent effects on human mesenchymal stem cells.
    Summary · context
    This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify and evaluate in vitro studies investigating the effects of glucagon-like peptide-1 receptor agonists and their analogues on human mesenchymal stem cell functions, including proliferation, differentiation, signaling, apoptosis, and tissue-specific applications.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 08LabNot a test of Liraglutide aloneIn vitro (cells)Efficacy outcome

    Across human mesenchymal stem cell studies, GLP-1 receptor agonists including liraglutide improved stem cell functions under diabetic or inflammatory conditions.

    In plain wordsIn lab tests, GLP-1 drugs including liraglutide improved stem-cell function in diabetic or inflammatory conditions.

    Peptide
    Liraglutide
    Outcome
    IncreaseMesenchymal stem cell function
    Study

    humann: not reported in source

    human mesenchymal stem cells
    Outcome group
    Cell proliferation and differentiation · Whole body

    Source sentences

    Summary
    Furthermore, these agents modulate inflammation, reduce apoptosis, and improve stem cell functions even under diabetic or inflammatory conditions.
    2 context sentences
    Summary · context
    Glucagon-like-peptide-1 receptor agonist, like native glucagon-like peptide-1, Exendin-4, and Liraglutide, exert context-, dose-, and timing-dependent effects on human mesenchymal stem cells.
    Summary · context
    This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify and evaluate in vitro studies investigating the effects of glucagon-like peptide-1 receptor agonists and their analogues on human mesenchymal stem cell functions, including proliferation, differentiation, signaling, apoptosis, and tissue-specific applications.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.